You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, September 2018
|
| DOI | 10.1186/s40425-018-0405-z |
| Pubmed ID | |
| Authors |
Javier Rodriguez, Eduardo Castañón, Jose Luis Perez-Gracia, Inmaculada Rodriguez, Antonio Viudez, Carlos Alfaro, Carmen Oñate, Guiomar Perez, Fernando Rotellar, Susana Inogés, Ascensión López-Diaz de Cerio, Leyre Resano, Mariano Ponz-Sarvise, Maria E. Rodriguez-Ruiz, Ana Chopitea, Ruth Vera, Ignacio Melero |
| Abstract |
Surgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite of standard-of-care neoadjuvant and adjuvant chemotherapy regimens. Dendritic cell vaccines loaded with autologous tumor lysates were tested for their potential to avoid or delay disease relapses (NCT01348256). Patients with surgically amenable liver metastasis of colon adenocarcinoma (n = 19) were included and underwent neoadjuvant chemotherapy, surgery and adjuvant chemotherapy. Fifteen patients with disease-free resection margins were randomized 1:1 to receive two courses of four daily doses of dendritic cell intradermal vaccinations versus observation. The trial had been originally designed to include 56 patients but was curtailed due to budgetary restrictions. Follow-up of the patients indicates a clear tendency to fewer and later relapses in the vaccine arm (median disease free survival -DFS-) 25.26 months, 95% CI 8.74-n.r) versus observation arm (median DFS 9.53 months, 95% CI 5.32-18.88). |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 40% |
| United Kingdom | 1 | 10% |
| Argentina | 1 | 10% |
| Unknown | 4 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 80% |
| Science communicators (journalists, bloggers, editors) | 1 | 10% |
| Scientists | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 72 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 14% |
| Researcher | 9 | 13% |
| Student > Master | 7 | 10% |
| Student > Bachelor | 7 | 10% |
| Student > Postgraduate | 4 | 6% |
| Other | 13 | 18% |
| Unknown | 22 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 19% |
| Biochemistry, Genetics and Molecular Biology | 12 | 17% |
| Immunology and Microbiology | 7 | 10% |
| Nursing and Health Professions | 4 | 6% |
| Engineering | 3 | 4% |
| Other | 8 | 11% |
| Unknown | 24 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2019.
All research outputs
#4,129,854
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,080
of 3,422 outputs
Outputs of similar age
#75,848
of 352,583 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#15
of 37 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,422 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,583 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.